CKD-506 has been found to have therapeutic effects in various colitis animal models. Therefore, this oral selective histone deacetylase 6 (HDAC6) inhibitor may exert beneficial effect in patients with Crohn’s disease and ulcerative colitis. The effect of CKD-506 on rheumatoid arthritis is already being evaluated in a clinical phase 2 study.
In the preclinical study presented at ECCO 2019, HDAC6 was overexpressed in colon tissue of patients with Crohn’s disease and ulcerative colitis . In vitro, HDAC6 overexpression by plasmid DNA strongly induced the production of various inflammatory mediators, especially TNFα, IL-6, IP-10, and ROS production from macrophages. However, CKD-506 inhibited HDAC6-mediated inflammatory responses in macrophages through NF-κB and AP-1. In vivo, CKD-506 strongly inhibited disease activity indexes in DSS-, TNBS-, piroxicam- (IL-10−/−)-, and adaptive T cell transfer-mediated colitis. In acute colitis models, CK...
please login to read the entire article:
You need to register to read the entire article, please do so now.
Table of Contents: ECCO 2019
New Compounds: Study Results
Short-term and Long-term Treatment Results
Complementary and Alternative Medicine
Basic and Preclinical Research
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.